The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Immunotherapy of Cancer Forum – ITOC

ITOC-LogoThe Immunotherapy of Cancer (ITOC) Forum addresses regulatory issues concerning new immunotherapies, hosts workshops and provides education around immunotherapy. It was organized by the CDDF with great success until 2019 and now continues under new management, Wiener Medizinische Akademie GmbH.

The conference, which is the largest immunotherapy meeting in Europe, includes plenary symposium, poster sessions, satellite symposium and an exhibition. The meeting is accredited by the European Council for Continuing Medical Education (EACCME). View more about the next annual conference on http://itoc-conference.eu/

The ITOC Education workshop on cancer immunotherapy presented by leading faculty in cancer immunotherapy, is designed for clinical oncologists, clinical scientists from industry, regulatory scientists, nurses, patient advocates, students and the entire medical team involved in treating cancer patients with immunotherapy. The course provides a greater understanding of cancer immunotherapies, their therapeutic effectiveness and the appropriate selection and management of cancer patients. The format will be a one-day programme, hosted at cancer meetings throughout the year. Discover more and join one course on http://itoc-conference.eu/itoc-education

The forum workshops on immunotherapies:

  • the EMA-CDDF Joint Meeting on the ‘Challenges for the Approval of Anti-Cancer Immunotherapeutic Drugs’ (London, UK – 4 & 5 February 2016)
  • the CDDF workshop on ‘Immuno Biomarker Development in the Peripheral Blood’ (Vienna, Austria – 7 & 8 December 2015)
Cancer Drug Development Forum
c/o BLSI
Clos Chapelle-aux-Champs 30
1200 Brussels, Belgium

info@cddf.org
Tel: +32 2 880 62 70

Legal address
c/o Deloitte Tirol
Wirtschaftsprüfungs GmbH,
Wilhelm-Greil-Str. 15,
6020 Innsbruck, Austria